Immunic is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases.
Immunic is based in the Munich biotech hub Martinsried and currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease and psoriasis. IMU-838 is currently being tested in a phase 2b trial in patients suffering from ulcerative colitis. A second phase 2 trial in patients with Crohn’s disease is planned to start in mid-2019. IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development. IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.